JP2002514180A - マトリックスメタロプロテイナーゼを阻害するための化合物およびその方法 - Google Patents
マトリックスメタロプロテイナーゼを阻害するための化合物およびその方法Info
- Publication number
- JP2002514180A JP2002514180A JP51281898A JP51281898A JP2002514180A JP 2002514180 A JP2002514180 A JP 2002514180A JP 51281898 A JP51281898 A JP 51281898A JP 51281898 A JP51281898 A JP 51281898A JP 2002514180 A JP2002514180 A JP 2002514180A
- Authority
- JP
- Japan
- Prior art keywords
- dibenzofuran
- sulfonylamino
- acid
- phenyl
- hexanoic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 125
- 238000000034 method Methods 0.000 title claims abstract description 58
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 7
- 102000002274 Matrix Metalloproteinases Human genes 0.000 title abstract description 28
- 108010000684 Matrix Metalloproteinases Proteins 0.000 title abstract description 28
- 150000001413 amino acids Chemical class 0.000 claims abstract description 18
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 16
- 206010019280 Heart failures Diseases 0.000 claims abstract description 13
- 201000011510 cancer Diseases 0.000 claims abstract description 13
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims abstract description 11
- 230000006378 damage Effects 0.000 claims abstract description 11
- 208000025865 Ulcer Diseases 0.000 claims abstract description 10
- 230000001684 chronic effect Effects 0.000 claims abstract description 10
- 208000037803 restenosis Diseases 0.000 claims abstract description 10
- 231100000397 ulcer Toxicity 0.000 claims abstract description 9
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 8
- 206010064996 Ulcerative keratitis Diseases 0.000 claims abstract description 8
- 208000007474 aortic aneurysm Diseases 0.000 claims abstract description 8
- 208000014674 injury Diseases 0.000 claims abstract description 8
- 210000000265 leukocyte Anatomy 0.000 claims abstract description 8
- 230000008733 trauma Effects 0.000 claims abstract description 8
- 206010027476 Metastases Diseases 0.000 claims abstract description 7
- 208000004210 Pressure Ulcer Diseases 0.000 claims abstract description 7
- 206010003246 arthritis Diseases 0.000 claims abstract description 7
- 230000009545 invasion Effects 0.000 claims abstract description 7
- 230000009401 metastasis Effects 0.000 claims abstract description 7
- 201000006417 multiple sclerosis Diseases 0.000 claims abstract description 7
- 208000028169 periodontal disease Diseases 0.000 claims abstract description 6
- 230000005747 tumor angiogenesis Effects 0.000 claims abstract description 6
- -1 D-iso Leucine Chemical compound 0.000 claims description 199
- 229910052739 hydrogen Inorganic materials 0.000 claims description 27
- 239000001257 hydrogen Substances 0.000 claims description 27
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 23
- 229940024606 amino acid Drugs 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 16
- 239000002253 acid Substances 0.000 claims description 15
- 125000000217 alkyl group Chemical group 0.000 claims description 13
- 150000002148 esters Chemical class 0.000 claims description 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
- 229910052736 halogen Inorganic materials 0.000 claims description 12
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 12
- 150000002367 halogens Chemical class 0.000 claims description 11
- 229910052717 sulfur Inorganic materials 0.000 claims description 11
- 241001024304 Mino Species 0.000 claims description 10
- 150000001408 amides Chemical class 0.000 claims description 10
- 125000001072 heteroaryl group Chemical group 0.000 claims description 9
- 229940002612 prodrug Drugs 0.000 claims description 8
- 239000000651 prodrug Substances 0.000 claims description 8
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 7
- 125000003118 aryl group Chemical group 0.000 claims description 7
- 239000011159 matrix material Substances 0.000 claims description 7
- 230000005764 inhibitory process Effects 0.000 claims description 6
- NDLHMLCMEBBXKC-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)pentanedioic acid Chemical compound C1=CC=C2C3=CC(S(=O)(=O)NC(CCC(=O)O)C(O)=O)=CC=C3OC2=C1 NDLHMLCMEBBXKC-UHFFFAOYSA-N 0.000 claims description 5
- 208000027866 inflammatory disease Diseases 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 206010011985 Decubitus ulcer Diseases 0.000 claims description 4
- 102000005741 Metalloproteases Human genes 0.000 claims description 4
- 108010006035 Metalloproteases Proteins 0.000 claims description 4
- 230000001363 autoimmune Effects 0.000 claims description 4
- 125000001624 naphthyl group Chemical group 0.000 claims description 4
- JENZVHXFRQGOFL-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-2-phenylacetic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1S(=O)(=O)NC(C(=O)O)C1=CC=CC=C1 JENZVHXFRQGOFL-UHFFFAOYSA-N 0.000 claims description 3
- RKWQDCZIHNOUDQ-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-5-[2-(1-methylpyrrol-2-yl)ethylamino]-5-oxopentanoic acid Chemical compound CN1C=CC=C1CCNC(=O)CCC(C(O)=O)NS(=O)(=O)C1=CC=C(OC=2C3=CC=CC=2)C3=C1 RKWQDCZIHNOUDQ-UHFFFAOYSA-N 0.000 claims description 3
- ZLNOARBTWFZMLC-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-5-oxo-5-(2-thiophen-2-ylethylamino)pentanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1S(=O)(=O)NC(C(=O)O)CCC(=O)NCCC1=CC=CS1 ZLNOARBTWFZMLC-UHFFFAOYSA-N 0.000 claims description 3
- OOWMSOXRLQBHJU-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-6-(3-pyridin-4-ylpropanoylamino)hexanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1S(=O)(=O)NC(C(=O)O)CCCCNC(=O)CCC1=CC=NC=C1 OOWMSOXRLQBHJU-UHFFFAOYSA-N 0.000 claims description 3
- MKGITNAOWOTDLE-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-6-(9h-fluoren-9-ylmethoxycarbonylamino)hexanoic acid Chemical compound C1=CC=C2C3=CC(S(=O)(=O)NC(CCCCNC(=O)OCC4C5=CC=CC=C5C5=CC=CC=C54)C(=O)O)=CC=C3OC2=C1 MKGITNAOWOTDLE-UHFFFAOYSA-N 0.000 claims description 3
- JQMYQNYDESVNOP-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-6-(naphthalen-2-ylcarbamothioylamino)hexanoic acid Chemical compound C1=CC=C2C3=CC(S(=O)(=O)NC(CCCCNC(=S)NC=4C=C5C=CC=CC5=CC=4)C(=O)O)=CC=C3OC2=C1 JQMYQNYDESVNOP-UHFFFAOYSA-N 0.000 claims description 3
- IFDYIIOZRLLFKE-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-6-[(2-indol-1-ylacetyl)amino]hexanoic acid Chemical compound C1=CC=C2C3=CC(S(=O)(=O)NC(CCCCNC(=O)CN4C5=CC=CC=C5C=C4)C(=O)O)=CC=C3OC2=C1 IFDYIIOZRLLFKE-UHFFFAOYSA-N 0.000 claims description 3
- QVAFZGJGISCWOW-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-6-[(2-naphthalen-1-ylacetyl)amino]hexanoic acid Chemical compound C1=CC=C2C3=CC(S(=O)(=O)NC(CCCCNC(=O)CC=4C5=CC=CC=C5C=CC=4)C(=O)O)=CC=C3OC2=C1 QVAFZGJGISCWOW-UHFFFAOYSA-N 0.000 claims description 3
- FZOUYLLHFHPZDI-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-6-[(2-naphthalen-1-yloxyacetyl)amino]hexanoic acid Chemical compound C1=CC=C2C3=CC(S(=O)(=O)NC(CCCCNC(=O)COC=4C5=CC=CC=C5C=CC=4)C(=O)O)=CC=C3OC2=C1 FZOUYLLHFHPZDI-UHFFFAOYSA-N 0.000 claims description 3
- JKSGPZSPMJSVPL-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-6-[(2-pyridin-4-ylsulfanylacetyl)amino]hexanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1S(=O)(=O)NC(C(=O)O)CCCCNC(=O)CSC1=CC=NC=C1 JKSGPZSPMJSVPL-UHFFFAOYSA-N 0.000 claims description 3
- WGQVBWGGZAEWDN-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-6-[(2-thiophen-2-ylacetyl)amino]hexanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1S(=O)(=O)NC(C(=O)O)CCCCNC(=O)CC1=CC=CS1 WGQVBWGGZAEWDN-UHFFFAOYSA-N 0.000 claims description 3
- NRJXEHVDVCJWFL-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-6-[(3,4-dichlorophenyl)carbamoylamino]hexanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1S(=O)(=O)NC(C(=O)O)CCCCNC(=O)NC1=CC=C(Cl)C(Cl)=C1 NRJXEHVDVCJWFL-UHFFFAOYSA-N 0.000 claims description 3
- CUFKDYVIEIYECR-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-6-[3-(4-methoxyphenyl)propanoylamino]hexanoic acid Chemical compound C1=CC(OC)=CC=C1CCC(=O)NCCCCC(C(O)=O)NS(=O)(=O)C1=CC=C(OC=2C3=CC=CC=2)C3=C1 CUFKDYVIEIYECR-UHFFFAOYSA-N 0.000 claims description 3
- NMDJIHJMEJGDIX-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-6-[[2-(4-methoxyphenoxy)acetyl]amino]hexanoic acid Chemical compound C1=CC(OC)=CC=C1OCC(=O)NCCCCC(C(O)=O)NS(=O)(=O)C1=CC=C(OC=2C3=CC=CC=2)C3=C1 NMDJIHJMEJGDIX-UHFFFAOYSA-N 0.000 claims description 3
- KLJMAQDORBAMIU-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)butanedioic acid Chemical compound C1=CC=C2C3=CC(S(=O)(=O)NC(CC(=O)O)C(O)=O)=CC=C3OC2=C1 KLJMAQDORBAMIU-UHFFFAOYSA-N 0.000 claims description 3
- VGLXBFPXVGHONM-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)butanoic acid Chemical compound C1=CC=C2C3=CC(S(=O)(=O)NC(CC)C(O)=O)=CC=C3OC2=C1 VGLXBFPXVGHONM-UHFFFAOYSA-N 0.000 claims description 3
- ODBAPUXLFYASCB-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)hexanedioic acid Chemical compound C1=CC=C2C3=CC(S(=O)(=O)NC(CCCC(=O)O)C(O)=O)=CC=C3OC2=C1 ODBAPUXLFYASCB-UHFFFAOYSA-N 0.000 claims description 3
- AUZKCSRJKIJLNS-UHFFFAOYSA-N 2-(dibenzothiophen-2-ylsulfonylamino)-4-phenylbutanoic acid Chemical compound C=1C=C2SC3=CC=CC=C3C2=CC=1S(=O)(=O)NC(C(=O)O)CCC1=CC=CC=C1 AUZKCSRJKIJLNS-UHFFFAOYSA-N 0.000 claims description 3
- ICBZSKCTKKUQSY-YUWZRIFDSA-N 4-[(1r,2s)-1-hydroxy-2-(methylamino)propyl]phenol;hydrochloride Chemical compound Cl.CN[C@@H](C)[C@H](O)C1=CC=C(O)C=C1 ICBZSKCTKKUQSY-YUWZRIFDSA-N 0.000 claims description 3
- IQUQANKEWZGZNK-UHFFFAOYSA-N 5-(benzylamino)-2-(dibenzofuran-2-ylsulfonylamino)-5-oxopentanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1S(=O)(=O)NC(C(=O)O)CCC(=O)NCC1=CC=CC=C1 IQUQANKEWZGZNK-UHFFFAOYSA-N 0.000 claims description 3
- HYWHALSAWYQPTB-UHFFFAOYSA-N 6-[(4-bromophenyl)sulfonylamino]-2-(dibenzofuran-2-ylsulfonylamino)hexanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1S(=O)(=O)NC(C(=O)O)CCCCNS(=O)(=O)C1=CC=C(Br)C=C1 HYWHALSAWYQPTB-UHFFFAOYSA-N 0.000 claims description 3
- SHCLWHWBMRSRKK-UHFFFAOYSA-N 6-[[2-(1,3-benzodioxol-5-yl)acetyl]amino]-2-(dibenzofuran-2-ylsulfonylamino)hexanoic acid Chemical compound C1=CC=C2C3=CC(S(=O)(=O)NC(CCCCNC(=O)CC=4C=C5OCOC5=CC=4)C(=O)O)=CC=C3OC2=C1 SHCLWHWBMRSRKK-UHFFFAOYSA-N 0.000 claims description 3
- DCUJUMYXAUIEAA-UHFFFAOYSA-N 6-[[2-(4-chlorophenoxy)-2-methylpropanoyl]amino]-2-(dibenzofuran-2-ylsulfonylamino)hexanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1S(=O)(=O)NC(C(O)=O)CCCCNC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 DCUJUMYXAUIEAA-UHFFFAOYSA-N 0.000 claims description 3
- ZDXPYRJPNDTMRX-GSVOUGTGSA-N D-glutamine Chemical compound OC(=O)[C@H](N)CCC(N)=O ZDXPYRJPNDTMRX-GSVOUGTGSA-N 0.000 claims description 3
- 239000004471 Glycine Substances 0.000 claims description 3
- YPOJAHGDLHWILP-IBGZPJMESA-N (2s)-2-(dibenzofuran-2-ylsulfonylamino)-4-phenylbutanoic acid Chemical compound C([C@@H](C(=O)O)NS(=O)(=O)C=1C=C2C3=CC=CC=C3OC2=CC=1)CC1=CC=CC=C1 YPOJAHGDLHWILP-IBGZPJMESA-N 0.000 claims description 2
- XGRQKCULXVSIPX-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-4-(1,3-dioxobenzo[f]isoindol-2-yl)butanoic acid Chemical compound C1=CC=C2C3=CC(S(=O)(=O)NC(CCN4C(C5=CC6=CC=CC=C6C=C5C4=O)=O)C(=O)O)=CC=C3OC2=C1 XGRQKCULXVSIPX-UHFFFAOYSA-N 0.000 claims description 2
- HADFOIXLELOUCE-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-4-(1,3-dioxoisoindol-2-yl)butanoic acid Chemical compound C1=CC=C2C3=CC(S(=O)(=O)NC(CCN4C(C5=CC=CC=C5C4=O)=O)C(=O)O)=CC=C3OC2=C1 HADFOIXLELOUCE-UHFFFAOYSA-N 0.000 claims description 2
- XUBNWLNTKGEZDX-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-4-(3-oxo-1h-isoindol-2-yl)butanoic acid Chemical compound C1=CC=C2C3=CC(S(=O)(=O)NC(CCN4C(C5=CC=CC=C5C4)=O)C(=O)O)=CC=C3OC2=C1 XUBNWLNTKGEZDX-UHFFFAOYSA-N 0.000 claims description 2
- FQXXJRIYXSNUIZ-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-5-(1,3-dioxobenzo[f]isoindol-2-yl)pentanoic acid Chemical compound C1=CC=C2C3=CC(S(=O)(=O)NC(CCCN4C(C5=CC6=CC=CC=C6C=C5C4=O)=O)C(=O)O)=CC=C3OC2=C1 FQXXJRIYXSNUIZ-UHFFFAOYSA-N 0.000 claims description 2
- ROCYKAXXYZPTDJ-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-5-(1,3-dioxoisoindol-2-yl)pentanoic acid Chemical compound C1=CC=C2C3=CC(S(=O)(=O)NC(CCCN4C(C5=CC=CC=C5C4=O)=O)C(=O)O)=CC=C3OC2=C1 ROCYKAXXYZPTDJ-UHFFFAOYSA-N 0.000 claims description 2
- MGVBRGIBDNQMJT-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-5-(3-oxo-1h-isoindol-2-yl)pentanoic acid Chemical compound C1=CC=C2C3=CC(S(=O)(=O)NC(CCCN4C(C5=CC=CC=C5C4)=O)C(=O)O)=CC=C3OC2=C1 MGVBRGIBDNQMJT-UHFFFAOYSA-N 0.000 claims description 2
- DMQDCKWVHYQISX-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-5-(phenylmethoxycarbonylamino)pentanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1S(=O)(=O)NC(C(=O)O)CCCNC(=O)OCC1=CC=CC=C1 DMQDCKWVHYQISX-UHFFFAOYSA-N 0.000 claims description 2
- OGJYDFVQYYKOEE-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-5-oxo-5-(2-pyridin-4-ylethylamino)pentanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1S(=O)(=O)NC(C(=O)O)CCC(=O)NCCC1=CC=NC=C1 OGJYDFVQYYKOEE-UHFFFAOYSA-N 0.000 claims description 2
- SPMXDDSXZOVALA-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-5-pyridin-3-ylpentanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1S(=O)(=O)NC(C(=O)O)CCCC1=CC=CN=C1 SPMXDDSXZOVALA-UHFFFAOYSA-N 0.000 claims description 2
- UUJPYVXIRFHAFR-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-6-(4-thiophen-2-ylbutanoylamino)hexanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1S(=O)(=O)NC(C(=O)O)CCCCNC(=O)CCCC1=CC=CS1 UUJPYVXIRFHAFR-UHFFFAOYSA-N 0.000 claims description 2
- CPAXWZYVQBSDOD-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-6-(phenylmethoxycarbonylamino)hexanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1S(=O)(=O)NC(C(=O)O)CCCCNC(=O)OCC1=CC=CC=C1 CPAXWZYVQBSDOD-UHFFFAOYSA-N 0.000 claims description 2
- ALMQENWFOJJCQE-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-6-(pyridin-3-ylcarbamothioylamino)hexanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1S(=O)(=O)NC(C(=O)O)CCCCNC(=S)NC1=CC=CN=C1 ALMQENWFOJJCQE-UHFFFAOYSA-N 0.000 claims description 2
- SNDIGWWLXHMQSH-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-6-[(2-pyridin-2-ylacetyl)amino]hexanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1S(=O)(=O)NC(C(=O)O)CCCCNC(=O)CC1=CC=CC=N1 SNDIGWWLXHMQSH-UHFFFAOYSA-N 0.000 claims description 2
- ATAVAGZOGOKAAC-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-6-[(2-pyridin-3-ylacetyl)amino]hexanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1S(=O)(=O)NC(C(=O)O)CCCCNC(=O)CC1=CC=CN=C1 ATAVAGZOGOKAAC-UHFFFAOYSA-N 0.000 claims description 2
- CLAMRBVWUQQDAY-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-6-[(4-methoxyphenyl)carbamoylamino]hexanoic acid Chemical compound C1=CC(OC)=CC=C1NC(=O)NCCCCC(C(O)=O)NS(=O)(=O)C1=CC=C(OC=2C3=CC=CC=2)C3=C1 CLAMRBVWUQQDAY-UHFFFAOYSA-N 0.000 claims description 2
- DWHWANYQSULZPQ-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-6-[3-(2-methoxyphenyl)propanoylamino]hexanoic acid Chemical compound COC1=CC=CC=C1CCC(=O)NCCCCC(C(O)=O)NS(=O)(=O)C1=CC=C(OC=2C3=CC=CC=2)C3=C1 DWHWANYQSULZPQ-UHFFFAOYSA-N 0.000 claims description 2
- ISYGRERUFBRMRI-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-6-[4-(4-nitrophenyl)butanoylamino]hexanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1S(=O)(=O)NC(C(=O)O)CCCCNC(=O)CCCC1=CC=C([N+]([O-])=O)C=C1 ISYGRERUFBRMRI-UHFFFAOYSA-N 0.000 claims description 2
- HEBZFDIZQHFSJO-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-6-[[2-(4-nitrophenoxy)acetyl]amino]hexanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1S(=O)(=O)NC(C(=O)O)CCCCNC(=O)COC1=CC=C([N+]([O-])=O)C=C1 HEBZFDIZQHFSJO-UHFFFAOYSA-N 0.000 claims description 2
- IQPDWXHYSLYWSL-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-6-[[2-[2,4,6-tri(propan-2-yl)phenyl]acetyl]amino]hexanoic acid Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1CC(=O)NCCCCC(C(O)=O)NS(=O)(=O)C1=CC=C(OC=2C3=CC=CC=2)C3=C1 IQPDWXHYSLYWSL-UHFFFAOYSA-N 0.000 claims description 2
- MJOFWSRQADJOGE-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)pent-4-enoic acid Chemical compound C1=CC=C2C3=CC(S(=O)(=O)NC(CC=C)C(=O)O)=CC=C3OC2=C1 MJOFWSRQADJOGE-UHFFFAOYSA-N 0.000 claims description 2
- WFAJDOBKNUJBGB-UHFFFAOYSA-N 2-[benzyl(dibenzofuran-2-ylsulfonyl)amino]-5-(4-ethylphenyl)pentanoic acid Chemical compound C1=CC(CC)=CC=C1CCCC(C(O)=O)N(S(=O)(=O)C=1C=C2C3=CC=CC=C3OC2=CC=1)CC1=CC=CC=C1 WFAJDOBKNUJBGB-UHFFFAOYSA-N 0.000 claims description 2
- DVJSNLUHKVYSMG-UHFFFAOYSA-N 2-[dibenzofuran-2-ylsulfonyl(2-phenoxyethyl)amino]pent-4-enoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1S(=O)(=O)N(C(CC=C)C(=O)O)CCOC1=CC=CC=C1 DVJSNLUHKVYSMG-UHFFFAOYSA-N 0.000 claims description 2
- BAMWOCBYJFLGLY-UHFFFAOYSA-N 2-[dibenzofuran-2-ylsulfonyl(methyl)amino]-5-(1,3-dioxoisoindol-2-yl)pentanoic acid Chemical compound C1=CC=C2C3=CC(S(=O)(=O)N(C(CCCN4C(C5=CC=CC=C5C4=O)=O)C(O)=O)C)=CC=C3OC2=C1 BAMWOCBYJFLGLY-UHFFFAOYSA-N 0.000 claims description 2
- LLBKYYZEQIIADV-UHFFFAOYSA-N 5-(4-chlorophenyl)-2-[dibenzofuran-2-ylsulfonyl(2-methylpropyl)amino]pentanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1S(=O)(=O)N(CC(C)C)C(C(O)=O)CCCC1=CC=C(Cl)C=C1 LLBKYYZEQIIADV-UHFFFAOYSA-N 0.000 claims description 2
- QWMFHKHNMHMHGU-UHFFFAOYSA-N 5-(4-chlorophenyl)-2-[dibenzofuran-2-ylsulfonyl(methyl)amino]pentanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1S(=O)(=O)N(C)C(C(O)=O)CCCC1=CC=C(Cl)C=C1 QWMFHKHNMHMHGU-UHFFFAOYSA-N 0.000 claims description 2
- JPGQZYDJVNHPMF-UHFFFAOYSA-N 6-(benzylcarbamothioylamino)-2-(dibenzofuran-2-ylsulfonylamino)hexanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1S(=O)(=O)NC(C(=O)O)CCCCNC(=S)NCC1=CC=CC=C1 JPGQZYDJVNHPMF-UHFFFAOYSA-N 0.000 claims description 2
- IVWZIOYXHUIFCT-UHFFFAOYSA-N 6-[(2-acetamido-1,3-thiazol-5-yl)sulfonylamino]-2-(dibenzofuran-2-ylsulfonylamino)hexanoic acid Chemical compound S1C(NC(=O)C)=NC=C1S(=O)(=O)NCCCCC(C(O)=O)NS(=O)(=O)C1=CC=C(OC=2C3=CC=CC=2)C3=C1 IVWZIOYXHUIFCT-UHFFFAOYSA-N 0.000 claims description 2
- SFNMSDQISATWSG-UHFFFAOYSA-N 6-[3-(4-chlorophenoxy)propanoylamino]-2-(dibenzofuran-2-ylsulfonylamino)hexanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1S(=O)(=O)NC(C(=O)O)CCCCNC(=O)CCOC1=CC=C(Cl)C=C1 SFNMSDQISATWSG-UHFFFAOYSA-N 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- GWSYENUVZWVUEP-UHFFFAOYSA-N C=1C=C2OC3=CC=CC=C3C2=CC=1S(=O)(=O)NC(CCCC)(C(O)=O)N(C(C)=O)C1=CCCC1 Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1S(=O)(=O)NC(CCCC)(C(O)=O)N(C(C)=O)C1=CCCC1 GWSYENUVZWVUEP-UHFFFAOYSA-N 0.000 claims description 2
- DCXYFEDJOCDNAF-UWTATZPHSA-N D-Asparagine Chemical compound OC(=O)[C@H](N)CC(N)=O DCXYFEDJOCDNAF-UWTATZPHSA-N 0.000 claims description 2
- XUJNEKJLAYXESH-UWTATZPHSA-N D-Cysteine Chemical compound SC[C@@H](N)C(O)=O XUJNEKJLAYXESH-UWTATZPHSA-N 0.000 claims description 2
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 claims description 2
- 229930195711 D-Serine Natural products 0.000 claims description 2
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims description 2
- 229930182846 D-asparagine Natural products 0.000 claims description 2
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims description 2
- 229930195715 D-glutamine Natural products 0.000 claims description 2
- HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical compound OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 claims description 2
- 229930195721 D-histidine Natural products 0.000 claims description 2
- ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 claims description 2
- 229930182819 D-leucine Natural products 0.000 claims description 2
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 claims description 2
- FFEARJCKVFRZRR-SCSAIBSYSA-N D-methionine Chemical compound CSCC[C@@H](N)C(O)=O FFEARJCKVFRZRR-SCSAIBSYSA-N 0.000 claims description 2
- 229930182818 D-methionine Natural products 0.000 claims description 2
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 claims description 2
- 229930182832 D-phenylalanine Natural products 0.000 claims description 2
- AYFVYJQAPQTCCC-STHAYSLISA-N D-threonine Chemical compound C[C@H](O)[C@@H](N)C(O)=O AYFVYJQAPQTCCC-STHAYSLISA-N 0.000 claims description 2
- 229930182822 D-threonine Natural products 0.000 claims description 2
- 229930182827 D-tryptophan Natural products 0.000 claims description 2
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 claims description 2
- OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 claims description 2
- 229930195709 D-tyrosine Natural products 0.000 claims description 2
- KZSNJWFQEVHDMF-SCSAIBSYSA-N D-valine Chemical compound CC(C)[C@@H](N)C(O)=O KZSNJWFQEVHDMF-SCSAIBSYSA-N 0.000 claims description 2
- 229930182831 D-valine Natural products 0.000 claims description 2
- 229930195710 D‐cysteine Natural products 0.000 claims description 2
- 201000007717 corneal ulcer Diseases 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 239000005947 Dimethoate Substances 0.000 claims 2
- XDLSSXYTUMNOHY-AWEZNQCLSA-N (3s)-3-[(dibenzofuran-2-ylsulfonylamino)methyl]-5-methylhexanoic acid Chemical compound C1=CC=C2C3=CC(S(=O)(=O)NC[C@@H](CC(C)C)CC(O)=O)=CC=C3OC2=C1 XDLSSXYTUMNOHY-AWEZNQCLSA-N 0.000 claims 1
- OPOAKKGPPSNINL-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-3-(4-hydroxyphenyl)sulfanylpropanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1S(=O)(=O)NC(C(=O)O)CSC1=CC=C(O)C=C1 OPOAKKGPPSNINL-UHFFFAOYSA-N 0.000 claims 1
- CHJPBQOZZLPRAI-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-4-oxo-4-(4-propylphenyl)butanoic acid Chemical compound C1=CC(CCC)=CC=C1C(=O)CC(C(O)=O)NS(=O)(=O)C1=CC=C(OC=2C3=CC=CC=2)C3=C1 CHJPBQOZZLPRAI-UHFFFAOYSA-N 0.000 claims 1
- SJNIHFRNNSGCOI-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-4-pyridin-3-ylbutanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1S(=O)(=O)NC(C(=O)O)CCC1=CC=CN=C1 SJNIHFRNNSGCOI-UHFFFAOYSA-N 0.000 claims 1
- SRZSAFSUWTXQMW-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-5-(2,2-diphenylethylamino)-5-oxopentanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1S(=O)(=O)NC(C(=O)O)CCC(=O)NCC(C=1C=CC=CC=1)C1=CC=CC=C1 SRZSAFSUWTXQMW-UHFFFAOYSA-N 0.000 claims 1
- LRTMILMJYXVICS-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-5-(2-hydroxypropylamino)-5-oxopentanoic acid Chemical compound C1=CC=C2C3=CC(S(=O)(=O)NC(CCC(=O)NCC(O)C)C(O)=O)=CC=C3OC2=C1 LRTMILMJYXVICS-UHFFFAOYSA-N 0.000 claims 1
- YEPAWRGTEBVAEZ-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-6-(2-phenoxybutanoylamino)hexanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1S(=O)(=O)NC(C(O)=O)CCCCNC(=O)C(CC)OC1=CC=CC=C1 YEPAWRGTEBVAEZ-UHFFFAOYSA-N 0.000 claims 1
- LUGWBOODZQKESV-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-6-(naphthalen-1-ylsulfonylamino)hexanoic acid Chemical compound C1=CC=C2C3=CC(S(=O)(=O)NC(CCCCNS(=O)(=O)C=4C5=CC=CC=C5C=CC=4)C(=O)O)=CC=C3OC2=C1 LUGWBOODZQKESV-UHFFFAOYSA-N 0.000 claims 1
- RNSICHYXRFBCKS-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-6-(naphthalen-2-ylsulfonylamino)hexanoic acid Chemical compound C1=CC=C2C3=CC(S(=O)(=O)NC(CCCCNS(=O)(=O)C=4C=C5C=CC=CC5=CC=4)C(=O)O)=CC=C3OC2=C1 RNSICHYXRFBCKS-UHFFFAOYSA-N 0.000 claims 1
- HOSXXBOASBEGAM-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-6-[(2-phenoxyacetyl)amino]hexanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1S(=O)(=O)NC(C(=O)O)CCCCNC(=O)COC1=CC=CC=C1 HOSXXBOASBEGAM-UHFFFAOYSA-N 0.000 claims 1
- NNIRCQIXFDXRIO-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-6-[(4-methoxyphenyl)sulfonylamino]hexanoic acid Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)NCCCCC(C(O)=O)NS(=O)(=O)C1=CC=C(OC=2C3=CC=CC=2)C3=C1 NNIRCQIXFDXRIO-UHFFFAOYSA-N 0.000 claims 1
- GINOMQNFRZQUEU-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-6-[3-(4-methylphenyl)propanoylamino]hexanoic acid Chemical compound C1=CC(C)=CC=C1CCC(=O)NCCCCC(C(O)=O)NS(=O)(=O)C1=CC=C(OC=2C3=CC=CC=2)C3=C1 GINOMQNFRZQUEU-UHFFFAOYSA-N 0.000 claims 1
- VPMDDYLEWAHAIQ-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-6-methoxy-6-oxohexanoic acid Chemical compound C1=CC=C2C3=CC(S(=O)(=O)NC(CCCC(=O)OC)C(O)=O)=CC=C3OC2=C1 VPMDDYLEWAHAIQ-UHFFFAOYSA-N 0.000 claims 1
- GPMOEPOQJSNHJY-UHFFFAOYSA-N 2-[dibenzofuran-2-ylsulfonyl(2-phenylethyl)amino]-5-phenylpentanoic acid Chemical compound C=1C=CC=CC=1CCN(S(=O)(=O)C=1C=C2C3=CC=CC=C3OC2=CC=1)C(C(=O)O)CCCC1=CC=CC=C1 GPMOEPOQJSNHJY-UHFFFAOYSA-N 0.000 claims 1
- UOCTXLFEKGNFBN-UHFFFAOYSA-N 2-[dibenzofuran-2-ylsulfonylmethyl(pyridin-3-yl)amino]-5-phenylpentanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1S(=O)(=O)CN(C=1C=NC=CC=1)C(C(=O)O)CCCC1=CC=CC=C1 UOCTXLFEKGNFBN-UHFFFAOYSA-N 0.000 claims 1
- ARPBYOKBGTWOFD-UHFFFAOYSA-N 4-(dibenzofuran-2-ylsulfonylamino)-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoic acid Chemical compound C1=CC=C2C3=CC(S(=O)(=O)NC(CCC(O)=O)C(=O)OC(C)(C)C)=CC=C3OC2=C1 ARPBYOKBGTWOFD-UHFFFAOYSA-N 0.000 claims 1
- GTMQOIKCXIIFNC-UHFFFAOYSA-N 5-(4-chloroanilino)-2-(dibenzofuran-2-ylsulfonylamino)-5-oxopentanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1S(=O)(=O)NC(C(=O)O)CCC(=O)NC1=CC=C(Cl)C=C1 GTMQOIKCXIIFNC-UHFFFAOYSA-N 0.000 claims 1
- DTIKAPURNLOPGK-UHFFFAOYSA-N 5-(cyclopropylamino)-2-(dibenzofuran-2-ylsulfonylamino)-5-oxopentanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1S(=O)(=O)NC(C(=O)O)CCC(=O)NC1CC1 DTIKAPURNLOPGK-UHFFFAOYSA-N 0.000 claims 1
- UQLLZBYSCGRCRT-UHFFFAOYSA-N 6-(1-adamantyloxycarbonylamino)-2-(dibenzofuran-2-ylsulfonylamino)hexanoic acid Chemical compound C1=CC=C2C3=CC(S(=O)(=O)NC(CCCCNC(=O)OC45CC6CC(CC(C6)C4)C5)C(=O)O)=CC=C3OC2=C1 UQLLZBYSCGRCRT-UHFFFAOYSA-N 0.000 claims 1
- ISPZLYXOBXILKM-UHFFFAOYSA-N 6-(benzhydrylcarbamothioylamino)-2-(dibenzofuran-2-ylsulfonylamino)hexanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1S(=O)(=O)NC(C(=O)O)CCCCNC(=S)NC(C=1C=CC=CC=1)C1=CC=CC=C1 ISPZLYXOBXILKM-UHFFFAOYSA-N 0.000 claims 1
- WVLFDMGQKDSLDH-UHFFFAOYSA-N 6-(benzylcarbamoylamino)-2-(dibenzofuran-2-ylsulfonylamino)hexanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1S(=O)(=O)NC(C(=O)O)CCCCNC(=O)NCC1=CC=CC=C1 WVLFDMGQKDSLDH-UHFFFAOYSA-N 0.000 claims 1
- BNAPSLZTYMVXRW-UHFFFAOYSA-N 6-[(4-acetamidophenyl)sulfonylamino]-2-(dibenzofuran-2-ylsulfonylamino)hexanoic acid Chemical compound C1=CC(NC(=O)C)=CC=C1S(=O)(=O)NCCCCC(C(O)=O)NS(=O)(=O)C1=CC=C(OC=2C3=CC=CC=2)C3=C1 BNAPSLZTYMVXRW-UHFFFAOYSA-N 0.000 claims 1
- OAFXXCOTPKUDEM-UHFFFAOYSA-N 6-[[2-(4-tert-butylphenoxy)acetyl]amino]-2-(dibenzofuran-2-ylsulfonylamino)hexanoic acid Chemical compound C1=CC(C(C)(C)C)=CC=C1OCC(=O)NCCCCC(C(O)=O)NS(=O)(=O)C1=CC=C(OC=2C3=CC=CC=2)C3=C1 OAFXXCOTPKUDEM-UHFFFAOYSA-N 0.000 claims 1
- WVKXNTAUFOYISS-UHFFFAOYSA-N 6-[acetyl(phenylsulfanyl)amino]-2-(dibenzofuran-2-ylsulfonylamino)hexanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1S(=O)(=O)NC(C(O)=O)CCCCN(C(=O)C)SC1=CC=CC=C1 WVKXNTAUFOYISS-UHFFFAOYSA-N 0.000 claims 1
- ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 claims 1
- 229930182847 D-glutamic acid Natural products 0.000 claims 1
- 229930182820 D-proline Natural products 0.000 claims 1
- LFVLUOAHQIVABZ-UHFFFAOYSA-N Iodofenphos Chemical compound COP(=S)(OC)OC1=CC(Cl)=C(I)C=C1Cl LFVLUOAHQIVABZ-UHFFFAOYSA-N 0.000 claims 1
- 229950004696 flusalan Drugs 0.000 claims 1
- 229960000310 isoleucine Drugs 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 8
- 208000037979 autoimmune inflammatory disease Diseases 0.000 abstract description 4
- 239000000243 solution Substances 0.000 description 32
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 28
- 238000006243 chemical reaction Methods 0.000 description 28
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 26
- 239000000203 mixture Substances 0.000 description 25
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 24
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 22
- 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 21
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 20
- 229920005989 resin Polymers 0.000 description 20
- 239000011347 resin Substances 0.000 description 20
- 102000000424 Matrix Metalloproteinase 2 Human genes 0.000 description 19
- 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- 239000003112 inhibitor Substances 0.000 description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
- 229910052757 nitrogen Inorganic materials 0.000 description 14
- 241000282414 Homo sapiens Species 0.000 description 12
- 108010016160 Matrix Metalloproteinase 3 Proteins 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 239000000047 product Substances 0.000 description 9
- 108091007196 stromelysin Proteins 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 102000029816 Collagenase Human genes 0.000 description 8
- 108060005980 Collagenase Proteins 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 229960002424 collagenase Drugs 0.000 description 8
- TXCDCPKCNAJMEE-UHFFFAOYSA-N dibenzofuran Chemical compound C1=CC=C2C3=CC=CC=C3OC2=C1 TXCDCPKCNAJMEE-UHFFFAOYSA-N 0.000 description 8
- 239000007858 starting material Substances 0.000 description 8
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 108010010803 Gelatin Proteins 0.000 description 7
- 230000003197 catalytic effect Effects 0.000 description 7
- 125000004093 cyano group Chemical group *C#N 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 229920000159 gelatin Polymers 0.000 description 7
- 239000008273 gelatin Substances 0.000 description 7
- 235000019322 gelatine Nutrition 0.000 description 7
- 235000011852 gelatine desserts Nutrition 0.000 description 7
- 239000011491 glass wool Substances 0.000 description 7
- 239000011550 stock solution Substances 0.000 description 7
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 150000001793 charged compounds Chemical class 0.000 description 6
- 238000001704 evaporation Methods 0.000 description 6
- 230000008020 evaporation Effects 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 125000003545 alkoxy group Chemical group 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 229920003180 amino resin Polymers 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical class C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 229940095574 propionic acid Drugs 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 5
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 4
- 102100027995 Collagenase 3 Human genes 0.000 description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
- 102000013382 Gelatinases Human genes 0.000 description 4
- 108010026132 Gelatinases Proteins 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical group OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- JTTHKOPSMAVJFE-VIFPVBQESA-N L-homophenylalanine Chemical compound OC(=O)[C@@H](N)CCC1=CC=CC=C1 JTTHKOPSMAVJFE-VIFPVBQESA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 4
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000004305 biphenyl Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 210000002744 extracellular matrix Anatomy 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 230000005012 migration Effects 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000010791 quenching Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000011593 sulfur Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 3
- 208000006029 Cardiomegaly Diseases 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 101000577887 Homo sapiens Collagenase 3 Proteins 0.000 description 3
- 239000007993 MOPS buffer Substances 0.000 description 3
- 102000056189 Neutrophil collagenases Human genes 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000002469 basement membrane Anatomy 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 235000010290 biphenyl Nutrition 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- ULCKEERECJMLHP-UHFFFAOYSA-N dibenzofuran-2-sulfonyl chloride Chemical compound C1=CC=C2C3=CC(S(=O)(=O)Cl)=CC=C3OC2=C1 ULCKEERECJMLHP-UHFFFAOYSA-N 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 210000004195 gingiva Anatomy 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 150000002430 hydrocarbons Chemical class 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000012948 isocyanate Substances 0.000 description 3
- 150000002513 isocyanates Chemical class 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- KDJDQQPHOKHMNW-UHFFFAOYSA-N methyl 6-amino-2-(dibenzofuran-2-ylsulfonylamino)hexanoate;hydrobromide Chemical compound Br.C1=CC=C2C3=CC(S(=O)(=O)NC(CCCCN)C(=O)OC)=CC=C3OC2=C1 KDJDQQPHOKHMNW-UHFFFAOYSA-N 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 230000020477 pH reduction Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 229940124530 sulfonamide Drugs 0.000 description 3
- 150000003456 sulfonamides Chemical class 0.000 description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- PLWQKTLARSQCGP-IBGZPJMESA-N (2s)-2-(dibenzothiophen-3-ylsulfonylamino)-4-phenylbutanoic acid Chemical compound C([C@@H](C(=O)O)NS(=O)(=O)C=1C=C2C(C3=CC=CC=C3S2)=CC=1)CC1=CC=CC=C1 PLWQKTLARSQCGP-IBGZPJMESA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- FGOJCPKOOGIRPA-UHFFFAOYSA-N 1-o-tert-butyl 4-o-ethyl 5-oxoazepane-1,4-dicarboxylate Chemical compound CCOC(=O)C1CCN(C(=O)OC(C)(C)C)CCC1=O FGOJCPKOOGIRPA-UHFFFAOYSA-N 0.000 description 2
- HDXHPZRRHOAZES-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-5-[2-(dimethylamino)ethylamino]-5-oxopentanoic acid Chemical compound C1=CC=C2C3=CC(S(=O)(=O)NC(CCC(=O)NCCN(C)C)C(O)=O)=CC=C3OC2=C1 HDXHPZRRHOAZES-UHFFFAOYSA-N 0.000 description 2
- GRBGXVIGTSHJNK-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-6-[3-(diethylamino)propanoylamino]hexanoic acid Chemical compound C1=CC=C2C3=CC(S(=O)(=O)NC(CCCCNC(=O)CCN(CC)CC)C(O)=O)=CC=C3OC2=C1 GRBGXVIGTSHJNK-UHFFFAOYSA-N 0.000 description 2
- RMYMVHKEXNIPSV-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-6-[[2-(2,4-dichlorophenoxy)acetyl]amino]hexanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1S(=O)(=O)NC(C(=O)O)CCCCNC(=O)COC1=CC=C(Cl)C=C1Cl RMYMVHKEXNIPSV-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 2
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 2
- REZRGUCAGQKDSR-UHFFFAOYSA-N 6-(1-adamantylcarbamothioylamino)-2-(dibenzofuran-2-ylsulfonylamino)hexanoic acid Chemical compound C1=CC=C2C3=CC(S(=O)(=O)NC(CCCCNC(=S)NC45CC6CC(CC(C6)C4)C5)C(=O)O)=CC=C3OC2=C1 REZRGUCAGQKDSR-UHFFFAOYSA-N 0.000 description 2
- XASCCVVJRAFIEI-UHFFFAOYSA-N 6-[(2-anilinoacetyl)amino]-2-(dibenzofuran-2-ylsulfonylamino)hexanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1S(=O)(=O)NC(C(=O)O)CCCCNC(=O)CNC1=CC=CC=C1 XASCCVVJRAFIEI-UHFFFAOYSA-N 0.000 description 2
- UEQKRBIWHTZDKU-UHFFFAOYSA-N 6-[4-(4-chloro-3-methylphenoxy)butanoylamino]-2-(dibenzofuran-2-ylsulfonylamino)hexanoic acid Chemical compound C1=C(Cl)C(C)=CC(OCCCC(=O)NCCCCC(NS(=O)(=O)C=2C=C3C4=CC=CC=C4OC3=CC=2)C(O)=O)=C1 UEQKRBIWHTZDKU-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 102000004318 Matrilysin Human genes 0.000 description 2
- 108090000855 Matrilysin Proteins 0.000 description 2
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 2
- 108010076497 Matrix Metalloproteinase 10 Proteins 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 101001013135 Rattus norvegicus Interstitial collagenase Proteins 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 102100028848 Stromelysin-2 Human genes 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 241000534944 Thia Species 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 2
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- AYJRCSIUFZENHW-UHFFFAOYSA-L barium carbonate Chemical compound [Ba+2].[O-]C([O-])=O AYJRCSIUFZENHW-UHFFFAOYSA-L 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 230000004709 cell invasion Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 201000002491 encephalomyelitis Diseases 0.000 description 2
- 238000003810 ethyl acetate extraction Methods 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 2
- 150000002220 fluorenes Chemical class 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000008384 membrane barrier Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000006225 natural substrate Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 230000003239 periodontal effect Effects 0.000 description 2
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 2
- 238000006277 sulfonation reaction Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 210000001179 synovial fluid Anatomy 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000007805 zymography Methods 0.000 description 2
- GKLQOPGOSKTMDW-QFIPXVFZSA-N (2s)-2-(9h-fluoren-2-ylsulfonylamino)-4-phenylbutanoic acid Chemical compound C([C@@H](C(=O)O)NS(=O)(=O)C=1C=C2C(C3=CC=CC=C3C2)=CC=1)CC1=CC=CC=C1 GKLQOPGOSKTMDW-QFIPXVFZSA-N 0.000 description 1
- NDLHMLCMEBBXKC-ZDUSSCGKSA-N (2s)-2-(dibenzofuran-2-ylsulfonylamino)pentanedioic acid Chemical compound C1=CC=C2C3=CC(S(=O)(=O)N[C@@H](CCC(=O)O)C(O)=O)=CC=C3OC2=C1 NDLHMLCMEBBXKC-ZDUSSCGKSA-N 0.000 description 1
- CKGCFBNYQJDIGS-LBPRGKRZSA-N (2s)-2-azaniumyl-6-(phenylmethoxycarbonylamino)hexanoate Chemical group [O-]C(=O)[C@@H]([NH3+])CCCCNC(=O)OCC1=CC=CC=C1 CKGCFBNYQJDIGS-LBPRGKRZSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 1
- LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical compound CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 125000000579 2,2-diphenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(C1=C([H])C([H])=C([H])C([H])=C1[H])C([H])([H])* 0.000 description 1
- SJPXJSANXSAHSU-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-3-(4-fluorophenyl)propanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1S(=O)(=O)NC(C(=O)O)CC1=CC=C(F)C=C1 SJPXJSANXSAHSU-UHFFFAOYSA-N 0.000 description 1
- COJSFTGHLOFDLF-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-3-[4-[(2-methylpropan-2-yl)oxy]phenyl]propanoic acid Chemical compound C1=CC(OC(C)(C)C)=CC=C1CC(C(O)=O)NS(=O)(=O)C1=CC=C(OC=2C3=CC=CC=2)C3=C1 COJSFTGHLOFDLF-UHFFFAOYSA-N 0.000 description 1
- AKGOCXPAZXSPOW-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-5-(2-methylbutylamino)-5-oxopentanoic acid Chemical compound C1=CC=C2C3=CC(S(=O)(=O)NC(CCC(=O)NCC(C)CC)C(O)=O)=CC=C3OC2=C1 AKGOCXPAZXSPOW-UHFFFAOYSA-N 0.000 description 1
- MTRHSROQRITLBQ-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-5-(4-methylpentan-2-ylamino)-5-oxopentanoic acid Chemical compound C1=CC=C2C3=CC(S(=O)(=O)NC(CCC(=O)NC(C)CC(C)C)C(O)=O)=CC=C3OC2=C1 MTRHSROQRITLBQ-UHFFFAOYSA-N 0.000 description 1
- PUWFHONXMCBSPN-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-5-[(4-methylphenyl)sulfonylamino]pentanoic acid Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NCCCC(C(O)=O)NS(=O)(=O)C1=CC=C(OC=2C3=CC=CC=2)C3=C1 PUWFHONXMCBSPN-UHFFFAOYSA-N 0.000 description 1
- HDHGKKSSTJLVPS-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-5-oxo-5-(2-phenylethylamino)pentanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1S(=O)(=O)NC(C(=O)O)CCC(=O)NCCC1=CC=CC=C1 HDHGKKSSTJLVPS-UHFFFAOYSA-N 0.000 description 1
- IEZZTTCMBWIYEC-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-5-oxo-5-(thiophen-2-ylmethylamino)pentanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1S(=O)(=O)NC(C(=O)O)CCC(=O)NCC1=CC=CS1 IEZZTTCMBWIYEC-UHFFFAOYSA-N 0.000 description 1
- RGNKVAABSWEEKX-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-5-phenylpentanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1S(=O)(=O)NC(C(=O)O)CCCC1=CC=CC=C1 RGNKVAABSWEEKX-UHFFFAOYSA-N 0.000 description 1
- KJFFSAMWNSAFLX-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-6-(2-phenylethenylsulfonylamino)hexanoic acid Chemical class C=1C=C2OC3=CC=CC=C3C2=CC=1S(=O)(=O)NC(C(=O)O)CCCCNS(=O)(=O)C=CC1=CC=CC=C1 KJFFSAMWNSAFLX-UHFFFAOYSA-N 0.000 description 1
- VMMQXFIQQBCZEK-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-6-(3,3,3-triphenylpropanoylamino)hexanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1S(=O)(=O)NC(C(=O)O)CCCCNC(=O)CC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 VMMQXFIQQBCZEK-UHFFFAOYSA-N 0.000 description 1
- MVDDWKMEAQHMRK-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-6-(phenylcarbamoylamino)hexanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1S(=O)(=O)NC(C(=O)O)CCCCNC(=O)NC1=CC=CC=C1 MVDDWKMEAQHMRK-UHFFFAOYSA-N 0.000 description 1
- IKAUYSNMEWLNGX-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-6-[(1-phenylcyclopropanecarbonyl)amino]hexanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1S(=O)(=O)NC(C(=O)O)CCCCNC(=O)C1(C=2C=CC=CC=2)CC1 IKAUYSNMEWLNGX-UHFFFAOYSA-N 0.000 description 1
- HMHKHUNQFYTFFA-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-6-[(2-phenylacetyl)amino]hexanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1S(=O)(=O)NC(C(=O)O)CCCCNC(=O)CC1=CC=CC=C1 HMHKHUNQFYTFFA-UHFFFAOYSA-N 0.000 description 1
- JAVKOMHYDZLWAO-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-6-[3-(3,4-dimethoxyphenyl)propanoylamino]hexanoic acid Chemical compound C1=C(OC)C(OC)=CC=C1CCC(=O)NCCCCC(C(O)=O)NS(=O)(=O)C1=CC=C(OC=2C3=CC=CC=2)C3=C1 JAVKOMHYDZLWAO-UHFFFAOYSA-N 0.000 description 1
- KPBBBCKEUARNPU-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-6-[4-(1h-indol-3-yl)butanoylamino]hexanoic acid Chemical compound C1=CC=C2C3=CC(S(=O)(=O)NC(CCCCNC(=O)CCCC=4C5=CC=CC=C5NC=4)C(=O)O)=CC=C3OC2=C1 KPBBBCKEUARNPU-UHFFFAOYSA-N 0.000 description 1
- OIRSIUQPVKOKCW-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-6-[[2-(3,4-dimethoxyphenyl)acetyl]amino]hexanoic acid Chemical compound C1=C(OC)C(OC)=CC=C1CC(=O)NCCCCC(C(O)=O)NS(=O)(=O)C1=CC=C(OC=2C3=CC=CC=2)C3=C1 OIRSIUQPVKOKCW-UHFFFAOYSA-N 0.000 description 1
- RUDZSTWVUDPCHC-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-6-phenylhexanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1S(=O)(=O)NC(C(=O)O)CCCCC1=CC=CC=C1 RUDZSTWVUDPCHC-UHFFFAOYSA-N 0.000 description 1
- CMDDUZWSCLDOQI-UHFFFAOYSA-N 2-(dibenzofuran-2-ylsulfonylamino)-7-phenylheptanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1S(=O)(=O)NC(C(=O)O)CCCCCC1=CC=CC=C1 CMDDUZWSCLDOQI-UHFFFAOYSA-N 0.000 description 1
- IUVCFHHAEHNCFT-INIZCTEOSA-N 2-[(1s)-1-[4-amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=C(F)C(OC(C)C)=CC=C1C(C1=C(N)N=CN=C11)=NN1[C@@H](C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC(F)=CC=C2O1 IUVCFHHAEHNCFT-INIZCTEOSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- OQUFOZNPBIIJTN-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;sodium Chemical compound [Na].OC(=O)CC(O)(C(O)=O)CC(O)=O OQUFOZNPBIIJTN-UHFFFAOYSA-N 0.000 description 1
- 125000002927 2-methoxybenzyl group Chemical group [H]C1=C([H])C([H])=C(C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- MIIIXQJBDGSIKL-UHFFFAOYSA-N 2-morpholin-4-ylethanesulfonic acid;hydrate Chemical compound O.OS(=O)(=O)CCN1CCOCC1 MIIIXQJBDGSIKL-UHFFFAOYSA-N 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- BYHDDXPKOZIZRV-UHFFFAOYSA-N 5-phenylpentanoic acid Chemical compound OC(=O)CCCCC1=CC=CC=C1 BYHDDXPKOZIZRV-UHFFFAOYSA-N 0.000 description 1
- XOMJTCOZOGDWGA-UHFFFAOYSA-N 6-(benzenesulfonamido)-2-(dibenzofuran-2-ylsulfonylamino)hexanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1S(=O)(=O)NC(C(=O)O)CCCCNS(=O)(=O)C1=CC=CC=C1 XOMJTCOZOGDWGA-UHFFFAOYSA-N 0.000 description 1
- CQWOOXHKYRGLPC-UHFFFAOYSA-N 6-(butylsulfonylamino)-2-(dibenzofuran-2-ylsulfonylamino)hexanoic acid Chemical compound C1=CC=C2C3=CC(S(=O)(=O)NC(CCCCNS(=O)(=O)CCCC)C(O)=O)=CC=C3OC2=C1 CQWOOXHKYRGLPC-UHFFFAOYSA-N 0.000 description 1
- KXPAZEANIKKBQX-UHFFFAOYSA-N 6-[(2-cyclopentyl-2-phenylacetyl)amino]-2-(dibenzofuran-2-ylsulfonylamino)hexanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1S(=O)(=O)NC(C(=O)O)CCCCNC(=O)C(C=1C=CC=CC=1)C1CCCC1 KXPAZEANIKKBQX-UHFFFAOYSA-N 0.000 description 1
- YRIGNTNVSFVIHE-UHFFFAOYSA-N 6-[3-(4-chlorophenyl)propanoylamino]-2-(dibenzofuran-2-ylsulfonylamino)hexanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1S(=O)(=O)NC(C(=O)O)CCCCNC(=O)CCC1=CC=C(Cl)C=C1 YRIGNTNVSFVIHE-UHFFFAOYSA-N 0.000 description 1
- YOBDKRDCOOCWQP-UHFFFAOYSA-N 6-[[2-(4-chlorophenoxy)acetyl]amino]-2-(dibenzofuran-2-ylsulfonylamino)hexanoic acid Chemical compound C=1C=C2OC3=CC=CC=C3C2=CC=1S(=O)(=O)NC(C(=O)O)CCCCNC(=O)COC1=CC=C(Cl)C=C1 YOBDKRDCOOCWQP-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 208000025494 Aortic disease Diseases 0.000 description 1
- 206010003162 Arterial injury Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 101000573945 Coccidioides posadasii (strain C735) Neutral protease 2 homolog MEP2 Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 229910021592 Copper(II) chloride Inorganic materials 0.000 description 1
- 206010011091 Coronary artery thrombosis Diseases 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AGPKZVBTJJNPAG-RFZPGFLSSA-N D-Isoleucine Chemical compound CC[C@@H](C)[C@@H](N)C(O)=O AGPKZVBTJJNPAG-RFZPGFLSSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 description 1
- 229930028154 D-arginine Natural products 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229930182845 D-isoleucine Natural products 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010060820 Joint injury Diseases 0.000 description 1
- 208000016593 Knee injury Diseases 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 229940124761 MMP inhibitor Drugs 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010076502 Matrix Metalloproteinase 11 Proteins 0.000 description 1
- 108010076503 Matrix Metalloproteinase 13 Proteins 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 208000034827 Neointima Diseases 0.000 description 1
- 108030001564 Neutrophil collagenases Proteins 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 101000925883 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Elastase Proteins 0.000 description 1
- 101000899851 Rattus norvegicus Guanylate cyclase 2D Proteins 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 101000584292 Streptomyces cacaoi Mycolysin Proteins 0.000 description 1
- 102100028847 Stromelysin-3 Human genes 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000005876 Tissue Inhibitor of Metalloproteinases Human genes 0.000 description 1
- 108010005246 Tissue Inhibitor of Metalloproteinases Proteins 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000007997 Tricine buffer Substances 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 241000051616 Ulmus minor Species 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 206010002906 aortic stenosis Diseases 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 159000000009 barium salts Chemical class 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N benzyl-alpha-carboxylic acid Natural products OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 125000006244 carboxylic acid protecting group Chemical group 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000003366 colagenolytic effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 208000002528 coronary thrombosis Diseases 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- WJTCGQSWYFHTAC-UHFFFAOYSA-N cyclooctane Chemical compound C1CCCCCCC1 WJTCGQSWYFHTAC-UHFFFAOYSA-N 0.000 description 1
- 239000004914 cyclooctane Substances 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 125000005265 dialkylamine group Chemical group 0.000 description 1
- 238000006193 diazotization reaction Methods 0.000 description 1
- YAXFSEZKMUVRDJ-UHFFFAOYSA-N dibenzofuran-1-sulfonamide Chemical class O1C2=CC=CC=C2C2=C1C=CC=C2S(=O)(=O)N YAXFSEZKMUVRDJ-UHFFFAOYSA-N 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- 201000011304 dilated cardiomyopathy 1A Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 238000003182 dose-response assay Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 235000019439 ethyl acetate Nutrition 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 210000000497 foam cell Anatomy 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000000477 gelanolytic effect Effects 0.000 description 1
- 208000024693 gingival disease Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940124508 injectable medicine Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- JWSMTBMIGYJJJM-UHFFFAOYSA-N magnesium;azane Chemical compound N.[Mg+2] JWSMTBMIGYJJJM-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 125000005487 naphthalate group Chemical group 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003349 osteoarthritic effect Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229940117803 phenethylamine Drugs 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- FQLQNUZHYYPPBT-UHFFFAOYSA-N potassium;azane Chemical compound N.[K+] FQLQNUZHYYPPBT-UHFFFAOYSA-N 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003334 secondary amides Chemical class 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 230000015590 smooth muscle cell migration Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- TXBNDGDMWKVRQW-UHFFFAOYSA-M sodium;2-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]azaniumyl]acetate;dodecyl sulfate Chemical compound [Na+].OCC(CO)(CO)NCC(O)=O.CCCCCCCCCCCCOS([O-])(=O)=O TXBNDGDMWKVRQW-UHFFFAOYSA-M 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229910052714 tellurium Inorganic materials 0.000 description 1
- PORWMNRCUJJQNO-UHFFFAOYSA-N tellurium atom Chemical compound [Te] PORWMNRCUJJQNO-UHFFFAOYSA-N 0.000 description 1
- CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 125000005309 thioalkoxy group Chemical group 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- FAKFSJNVVCGEEI-UHFFFAOYSA-J tin(4+);disulfate Chemical compound [Sn+4].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O FAKFSJNVVCGEEI-UHFFFAOYSA-J 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000002689 xenotransplantation Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/76—Dibenzothiophenes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Lubricants (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Furan Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2506396P | 1996-09-04 | 1996-09-04 | |
| US60/025,063 | 1996-09-04 | ||
| US5571497P | 1997-08-07 | 1997-08-07 | |
| US60/055,714 | 1997-08-07 | ||
| PCT/US1997/015444 WO1998009957A1 (en) | 1996-09-04 | 1997-09-02 | Compounds for and a method of inhibiting matrix metalloproteinases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002514180A true JP2002514180A (ja) | 2002-05-14 |
| JP2002514180A5 JP2002514180A5 (https=) | 2005-04-07 |
Family
ID=26699217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP51281898A Abandoned JP2002514180A (ja) | 1996-09-04 | 1997-09-02 | マトリックスメタロプロテイナーゼを阻害するための化合物およびその方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6294674B1 (https=) |
| EP (1) | EP0929542A1 (https=) |
| JP (1) | JP2002514180A (https=) |
| KR (1) | KR20000068415A (https=) |
| AU (1) | AU736347B2 (https=) |
| BR (1) | BR9712794A (https=) |
| CA (1) | CA2256631A1 (https=) |
| HR (1) | HRP970474B1 (https=) |
| NZ (1) | NZ333064A (https=) |
| WO (1) | WO1998009957A1 (https=) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010073719A1 (ja) * | 2008-12-26 | 2010-07-01 | 国立大学法人京都大学 | Eg5阻害剤 |
| JP2019507130A (ja) * | 2016-02-01 | 2019-03-14 | バイオクリスト ファーマスーティカルズ,インコーポレイテッドBiocryst Pharmaceuticals,Inc. | ベンゾピラゾール化合物及びその類似体 |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100413859C (zh) * | 1996-01-23 | 2008-08-27 | 盐野义制药株式会社 | 磺化的氨基酸衍生物及含有它的金属蛋白酶抑制剂 |
| US6919375B1 (en) | 1996-01-23 | 2005-07-19 | Shionogi & Co., Ltd. | Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same |
| CA2263886A1 (en) * | 1996-12-09 | 1998-06-18 | Warner-Lambert Company | Method for treating and preventing heart failure and ventricular dilatation |
| ATE261954T1 (de) * | 1998-07-30 | 2004-04-15 | Warner Lambert Co | Tricyclische sulfonamide und ihre derivate als inhibitoren von matrix-metalloproteinasen |
| WO2000006560A1 (en) * | 1998-07-30 | 2000-02-10 | Warner-Lambert Company | Tricyclic heteroaromatics and their derivatives as inhibitors of matrix metalloproteinases |
| WO2000015213A1 (en) * | 1998-09-11 | 2000-03-23 | Shionogi & Co., Ltd. | Remedal or preventive agent for congestive heart failure |
| PL358272A1 (en) * | 2000-03-27 | 2004-08-09 | The Scripps Research Institute | Methods for inhibiting angiogenesis and tumor growth |
| GB2365425A (en) * | 2000-08-01 | 2002-02-20 | Parke Davis & Co Ltd | Alkyl amino acid derivatives useful as pharmaceutical agents |
| US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US7232924B2 (en) | 2001-06-11 | 2007-06-19 | Xenoport, Inc. | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs |
| US7186855B2 (en) | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US6818787B2 (en) | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US20030129672A1 (en) * | 2001-08-29 | 2003-07-10 | Dyer Richard Dennis | Method for identifying metalloenzyme inhibitors |
| PE20030701A1 (es) | 2001-12-20 | 2003-08-21 | Schering Corp | Compuestos para el tratamiento de trastornos inflamatorios |
| EP2181704B1 (en) | 2002-12-30 | 2015-05-06 | Angiotech International Ag | Drug delivery from rapid gelling polymer composition |
| CN1318411C (zh) * | 2005-03-21 | 2007-05-30 | 中国海洋大学 | 氢化轮枝霉酮类化合物及其制备方法和用途 |
| AU2006332694A1 (en) * | 2005-12-30 | 2007-07-12 | Alantos Pharmaceuticals, Holding, Inc. | Substituted bis-amide metalloprotease inhibitors |
| WO2008057254A2 (en) * | 2006-10-27 | 2008-05-15 | Wyeth | Tricyclic compounds as matrix metalloproteinase inhibitors |
| GB0621973D0 (en) * | 2006-11-03 | 2006-12-13 | Philogen Spa | Binding molecules and uses thereof |
| CL2008001257A1 (es) * | 2007-05-04 | 2008-07-04 | Wyeth Corp | Compuestos triciclicos, inhibidores de metaloproteinasas matriciales; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como artritis reumatoide, osteoartritis, aterosclerosis, cancer de pulmon, entre otras. |
| BRPI0813176A2 (pt) * | 2007-06-15 | 2014-12-30 | Mission Pharma Co | Moléculas e composições par ainibir fator edema e adenilil ciclase |
| CN114981251B (zh) * | 2020-01-21 | 2023-11-21 | 深圳信立泰药业股份有限公司 | 一种二苯并呋喃类衍生物组织蛋白酶k抑制剂及其制备方法和医药用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845097A (en) | 1969-09-06 | 1974-10-29 | Ajinomoto Kk | N-substituted amino acids and novel ester |
| DE2065966C3 (de) | 1969-09-06 | 1978-11-16 | Ajinomoto Co., Inc., Tokio | N-Fluorenyl-sulfonyl-aminocarbonsäuren sowie diese enthaltende Mittel |
| US4097472A (en) | 1974-11-08 | 1978-06-27 | Mitsubishi Chemical Industries Limited | N2 -arylsulfonyl-l-argininamides and the pharmaceutically acceptable salts thereof |
| DE2236876C3 (de) * | 1971-08-19 | 1981-02-12 | Ajinomoto Co., Inc., Tokio | N-Substituierte Aminocarbonsäuren und diese Verbindungen enthaltende Arzneimittel |
| EP0183271B1 (en) * | 1984-11-30 | 1990-05-16 | Shosuke Okamoto | Lysin derivative and proteinase inhibitor |
| PH31294A (en) * | 1992-02-13 | 1998-07-06 | Thomae Gmbh Dr K | Benzimidazolyl derivatives, pharmaceutical compositions containing these compounds and process for preparing them. |
| US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| US5665764A (en) | 1995-06-02 | 1997-09-09 | Warner-Lambert Company | Tricyclic inhibitors of matrix metalloproteinases |
| US5627206A (en) | 1995-06-02 | 1997-05-06 | Warner-Lambert Company | Tricyclic inhibitor of matrix metalloproteinases |
| JPH11506097A (ja) | 1995-06-02 | 1999-06-02 | ワーナー−ランバート・コンパニー | マトリックスメタロプロテイナーゼの三環式阻害剤 |
| IL123901A (en) | 1995-11-17 | 2003-06-24 | Warner Lambert Co | Sulfonamide inhibitors of matrix metalloproteinases and pharmaceutical compositions comprising them |
| CN100413859C (zh) * | 1996-01-23 | 2008-08-27 | 盐野义制药株式会社 | 磺化的氨基酸衍生物及含有它的金属蛋白酶抑制剂 |
| BR9711988A (pt) | 1996-09-04 | 1999-08-24 | Warner Lambert Co | Inibidores de metaloproteinase de matriz e seus empregos terap-uticos |
-
1997
- 1997-09-02 CA CA002256631A patent/CA2256631A1/en not_active Abandoned
- 1997-09-02 AU AU41770/97A patent/AU736347B2/en not_active Ceased
- 1997-09-02 WO PCT/US1997/015444 patent/WO1998009957A1/en not_active Ceased
- 1997-09-02 US US09/254,403 patent/US6294674B1/en not_active Expired - Fee Related
- 1997-09-02 NZ NZ333064A patent/NZ333064A/xx unknown
- 1997-09-02 EP EP97939751A patent/EP0929542A1/en not_active Withdrawn
- 1997-09-02 JP JP51281898A patent/JP2002514180A/ja not_active Abandoned
- 1997-09-02 KR KR1019997001757A patent/KR20000068415A/ko not_active Abandoned
- 1997-09-02 BR BR9712794-9A patent/BR9712794A/pt not_active Application Discontinuation
- 1997-09-04 HR HR970474A patent/HRP970474B1/xx not_active IP Right Cessation
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010073719A1 (ja) * | 2008-12-26 | 2010-07-01 | 国立大学法人京都大学 | Eg5阻害剤 |
| JP2019507130A (ja) * | 2016-02-01 | 2019-03-14 | バイオクリスト ファーマスーティカルズ,インコーポレイテッドBiocryst Pharmaceuticals,Inc. | ベンゾピラゾール化合物及びその類似体 |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20000068415A (ko) | 2000-11-25 |
| BR9712794A (pt) | 1999-12-14 |
| NZ333064A (en) | 2000-11-24 |
| WO1998009957A1 (en) | 1998-03-12 |
| US6294674B1 (en) | 2001-09-25 |
| AU736347B2 (en) | 2001-07-26 |
| HRP970474B1 (en) | 2002-10-31 |
| AU4177097A (en) | 1998-03-26 |
| CA2256631A1 (en) | 1998-03-12 |
| EP0929542A1 (en) | 1999-07-21 |
| HRP970474A2 (en) | 1998-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002514180A (ja) | マトリックスメタロプロテイナーゼを阻害するための化合物およびその方法 | |
| KR100352316B1 (ko) | 메탈로프로테아제억제제로서사용되는술포닐아미노치환히드록삼산유도체 | |
| US6117869A (en) | Compounds for and methods of inhibiting matrix metalloproteinases | |
| EP0960108B1 (en) | Matrix metalloproteinase inhibitors | |
| AU735013B2 (en) | Matrix metalloproteinase inhibitors and their therapeutic uses | |
| AU737117B2 (en) | Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing | |
| KR20000035925A (ko) | 매트릭스 메탈로프로테아제 저해제인 포스핀산 아미드 | |
| EP0586537A1 (en) | Substituted n-carboxyalkylpeptidyl derivatives as antidegenerative active agents | |
| KR20000035917A (ko) | 1,4-헤테로고리성 메탈로프로테아제 저해제 | |
| MXPA98001093A (en) | Inhibitors of proteinase c for the treatment of diseases related to the overproduction of colag | |
| JP2000511175A (ja) | ビフェニルスルホンアミドマトリックスメタロプロテイナーゼ阻害剤 | |
| JPH08503475A (ja) | 抗変性活性剤としてのカルボキシ−ペプチジル誘導体 | |
| CZ195298A3 (cs) | Aromatické keto-kyseliny a jejich deriváty jako inhibitory matricových metaloproteináz | |
| US5679700A (en) | Substituted phosphinic acid-containing peptidyl derivatives as antidegenerative agents | |
| JPH04210966A (ja) | 新規化合物、その製法及びそれを含む医薬組成物 | |
| WO1994007481A1 (en) | N-(mercaptoacyl)peptidyl derivatives as antidegenerative agents | |
| PT828726E (pt) | Inibidores triciclicos de metaloproteinases de matriz | |
| US6624177B1 (en) | Matrix metalloproteinase inhibitors and their therapeutic uses | |
| US6090785A (en) | Substituted N-carboxyalkylpeptidyl derivatives as antidegenerative agents | |
| ZA200103605B (en) | Cystine derivatives as therapeutic agents for matrix metalloprotease related diseases. | |
| EP0723974A1 (fr) | Dérivés de mercaptoalcanoyldipeptides, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
| MXPA98009929A (en) | Compounds for and a method of inhibiting matrix metalloproteinases | |
| US5932551A (en) | Substituted N-carboxyalkylpeptidyl derivatives as antidegenerative active agents | |
| MXPA98009871A (en) | Matrix metalloproteinase inhibitors and their therapeutic uses | |
| FR2973374A1 (fr) | Nouveaux alkylthioethers, leur preparation et leur application en therapeutique |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040819 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040819 |
|
| A72 | Notification of change in name of applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A721 Effective date: 20060306 |
|
| A762 | Written abandonment of application |
Free format text: JAPANESE INTERMEDIATE CODE: A762 Effective date: 20060306 |